
Woman, 30, medically declared brain-dead is pregnant while on life support
A 30-year-old woman on life support in the intensive care unit of a hospital in Atlanta, Georgia, is expecting a baby.
a local nurse, was nine weeks pregnant when she went to a hospital in February seeking treatment for intense headaches.
Doctors sent her home with some medication but they didn't conduct a CT scan. The next morning she woke up struggling to breathe.
The hospital discovered the mother-of-one had blood clots in her brain and, after an unsuccessful surgery to relieve the pressure, she was declared brain-dead.
Critics argue the situation has turned from tragedy into 'an absolute horror show' after Emory University Hospital – where the nurse previously worked – informed Adriana's family that, although she was legally dead, she was not allowed to die.
The apparent reason, according to the hospital's spokesman, is that it's acting 'in compliance with Georgia's abortion laws'.
As such, the hospital has reportedly demanded Adriana be kept alive on breathing and feeding tubes until specialists have determined the male foetus is sufficiently developed to be delivered – by caesarean section – as a baby boy. That is scheduled to occur in early August.
Removing her from life-support until that time, health officials reportedly believe, would violate Georgia's strict anti-abortion laws – which prohibit termination once a foetal heartbeat is detected, typically at around six weeks.
The state's controversial law, the Living Infants Fairness And Equality (LIFE) Act, which was dubbed the 'Heartbeat Bill' does contain an exception to save the life of the mother. But that doesn't apply to Adriana, as her life is beyond saving.
Her family say they haven't made up their minds whether to switch off her life-support systems but, at this moment, are deeply upset that the decision has been taken out of their hands by faceless bureaucrats.
'This is torture for me,' her distraught mother April Newkirk told local TV station 11Alive. 'I see my daughter breathing by the ventilator but she's not there.'
She revealed that the baby - who the family have named 'Chance' – has hydrocephalus, or fluid on the brain. Even if he survives the pregnancy (which is increasingly uncertain), he could be born with severe disabilities.
Newkirk added: 'He may be blind, may not be able to walk, may not survive once he's born. Right now, the journey is for baby "Chance" to survive. Whatever condition God allows him to come here in, we're going to love him just the same.'
While Georgia's 'Heartbeat Law' was narrowly passed in 2019, it did not come into effect until three years later after the Supreme Court overturned Roe V Wade, the 1973 case that established a woman's constitutional right to an abortion.
Three other states have similar abortion bans that come into force around the six-week mark and 12 states bar abortion at all stages of pregnancy.
Legal experts are in little doubt what is worrying Adriana's healthcare provider – a part of the Georgia law that gives foetuses legal rights.
If Adriana and the foetus are two patients with separate legal rights, even if the mother dies, the hospital might have a legal obligation to keep the foetus alive.
But doctors anticipate there will be more problems for the child, pointing out life-support systems are not designed for long-term treatment of brain-dead patients.
With blood no longer running to the mother's brain, the organ is starting to decompose.
'The chance of there being a healthy newborn at the end of this is very, very small,' said Steven Ralston, the director of the maternal foetal medicine division at George Washington University in Washington DC.
The medical situation and apparent helplessness of Adriana's family has sparked the ire of the 'pro-choice', pro-abortion lobby, with critics saying the case demonstrates a 'pro-life' philosophy that ends up being anything but humane.
Predictably, some opponents have likened Georgia to Gilead, the fictional U.S. in Margaret Atwood's chilling novel The Handmaid's Tale.
In this dystopian world, much of the U.S. is ruled by a brutal Christian fundamentalist government which – to tackle a severe infertility crisis – forces the few women who can conceive to devote their lives to producing offspring for ruling men.
While drawing an analogy with the book is once again a fairly extreme view, critics are correct in saying the state's leaders should have seen this coming.
Legal experts say the vague way anti-abortion laws are written will naturally make doctors and hospitals worried about facing criminal charges.
And they should have foreseen, too, how the movement to establish so-called 'foetal personhood' – whereby a foetus should have legal rights, including the right to life – would inevitably end up pitting the rights of the mother against those of their unborn child.
Now, keen to avert a public relations crisis that could lose them votes in a key swing state, even some of Georgia's conservatives are fighting back by claiming that the state's LIFE law is being misinterpreted.
The state's Republican attorney general, Chris Carr, declared last week that the law does not require doctors to keep brain-dead patients alive because turning off the life support 'is not an action with the purpose to terminate a pregnancy'.
Others disagree, however, and say the hospital has taken the correct – and humane – course.
'While Adriana can no longer speak for herself, her son's life still matters. Her doctors are doing the right thing by treating him as a unique patient,' said Students For Life Of America, a national anti-abortion group which has even launched a campaign to raise money to help Adriana's family.
Georgia state Senator Ed Setzler, who sponsored the state's abortion crackdown, has agreed, saying: 'I think there's a valuable human life that we have an opportunity to save, and I think it's the right thing to save it. To suggest otherwise is to declare the child as being other than human.
'This is an unusual circumstance, but I think it highlights the value of innocent human life.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Daily Mail
an hour ago
- Daily Mail
Bombshell research shows weight-loss drugs like Ozempic don't work as well as companies boasted
Blockbuster weight loss drugs like Ozempic might not work as well as advertised, a bombshell study reveals. A Cleveland Clinic study found patients taking semaglutide and tirzepatide - the active ingredients in Ozempic, Wegovy and Mounjaro - lost up to 50 percent less weight than what drug companies reported in clinical trials. They were also 40 percent more likely to go off the drugs within a year than patients in trials for reasons such as side effects being too severe. In the new study, researchers looked at nearly 8,000 obese Americans who were prescribed either semaglutide or tirzepatide for a year. One in five stopped taking the drugs within three months and nearly one in three stopped before the end of the year. Patients in the new study lost anywhere from four to 12 percent of their body weight in a year depending on how long they stayed on the drugs. But in the drugs' clinical trials, they lost between 15 and 21 percent of their weight. The researchers said the disparity could be due to higher rates of patients stopping the drugs and patients using lower doses than those in clinical trials. Patients also complained of high drug costs and harsh side effects, which have included stomach paralysis and blindness in severe cases. Dr Hamlet Gasoyan, lead study author and researcher at Cleveland Clinic's Center for Value-Based Care, said: 'Our study shows that patients treated for obesity with semaglutide or trizepatide lost less weight on average in a regular clinical setting compared to what is observed in randomized clinical trials. 'According to our data, this could be explained by higher rates of discontinuation and lower maintenance dosages used in clinical practice, compared to randomized clinical trial settings.' About one in eight Americans report taking a GLP-1 agonist like Ozempic or Wegovy at some point in their lives. And recent research shows their popularity has soared 600 percent since 2019. The study, published Tuesday in Obesity Journal, looked at 7,881 adults patients obese patients using electronic health data. The majority (6,109) received semaglutide while the remainder took tirzepatide. It's unclear if they took specific brand names like Ozempic or Wegovy. The average participant age was 51 and three in four patients were women. Their average body mass index (BMI) was 39, which is considered 'severe obesity.' Any BMI over 30 is obese. Of those patients, 1,320 had prediabetes, a precursor to type 2 diabetes that affects 100million Americans, most of whom don't know they have it. Participants began taking semaglutide or tirzepatide for obesity between 2021 and 2023. Those that stopped taking the drugs within three months were considered 'early' discontinuers and those who stopped in three to 12 months were 'late' discontinuers. Researchers found about 20 percent of participants stopped taking the GLP-1 drugs early and 32 percent stopped late. Additionally, 80 percent were on lower maintenance doses than when they started. This was the equivalent of 1 mg or less of semaglutide or less than 7.5 mg of tirzepatide. A maintenence dose is the amount needed to sustain weight loss. After one year, people who stopped taking the drug early had a four percent weight reduction compared to seven percent for those who stopped late. The above graph shows weight reductions in patients who stopped taking weight loss drugs within three months, in three to 12 months and who never stopped Those who stayed on the drugs for the full year lost 12 percent, and participants who kept with the drugs and took higher maintenance dosages lost 14 percent body weight on semaglutide and 18 percent on tirzepatide. In semaglutide and tirzepatide's clinical trials, patients lost between 15 and 21 percent of their weight after one year, up to 50 percent less than those in the new study who stayed on the drugs for a year. The researchers believe participants lost less weight than those in clinical trials promoted by drug companies because they were more likely to stop taking the drugs, hampering their progress. They cited clinical trials showing patients discontinued the drugs at a rate of 17 percent, up to 40 percent less often. Patients in clinical trials were also more likely to take higher doses. Dr Gasoyan said: 'Our findings about the real-world use patterns of these medications and associated clinical outcomes could inform the decisions of healthcare providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions.' The team found patients most commonly stopped taking weight loss drugs due to high costs, issues with insurance coverage, risk of side effects and medication shortages.


Daily Mail
2 hours ago
- Daily Mail
Revealed: The game-changing new test that can spot a severe condition endured by millions of women early - and spare them from years of agony
It affects one in ten women, causes severe pain and can reduce the chances of having a child. And yet it can take years for endometriosis – where tissue similar to the lining of the womb grows in other parts of the body – to be diagnosed; some women suffer for almost a decade before it is identified.


The Independent
2 hours ago
- The Independent
Study finds link between teenage sleep habits and adult heart health
A study by the American Academy of Sleep Medicine found that teenagers with better sleep habits at age 15 showed improved heart health seven years later. Healthy sleep habits include falling asleep and waking up earlier, spending less time awake in bed, and having less variability in total sleep time and sleep onset. The study, backed by the National Institutes of Health, analysed data from 307 adults, mainly girls, using wrist devices to measure sleep variables at age 15 and assessing cardiovascular health at age 22. Cardiovascular health was evaluated based on diet, physical activity, nicotine exposure, BMI, and measurements of blood fats, blood sugar, and blood pressure, scored using the American Heart Association's Life's Essential 8. Dr. Gina Marie Mathew, the lead data analyst, emphasised the need for a comprehensive approach to sleep health, highlighting the importance of earlier sleep timing, higher sleep maintenance efficiency, and lower sleep variability for long-term heart health.